

## Bausch + Lomb Acquires Diagnostic Company Trukera Medical

VAUGHAN, Ontario, July 23, 2024 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced an affiliate has acquired Trukera Medical, from its private equity owner, AccelMed Partners, and other shareholders. The tuck-in acquisition will help expand Bausch + Lomb’s surgical presence in the United States and contribute to its leading position in dry eye.

Trukera Medical, a U.S.-based privately held ophthalmic medical diagnostic company, commercializes ScoutPro<sup>®</sup>, a point-of-care portable device for precisely measuring osmolarity, or the salt content of a person’s tears. Hyperosmolarity, a condition not detectable by slit lamp examination, is a leading indicator and central etiology of asymptomatic dry eye disease (DED) and ocular surface disease (OSD), which can negatively affect corneal, cataract and refractive surgery outcomes if not treated effectively prior to the procedure.

“As a global leader in dry eye disease management, as well as cataract and refractive medical devices and implants, we’re uniquely positioned to optimize pre-surgical preparation to help ensure positive post-surgical outcomes,” said Luc Bonnefoy, president, Surgical, Bausch + Lomb. “ScoutPro has already become a valuable preoperative diagnostic tool for many U.S. surgeons, and with our scale we believe it can have an even greater impact.”

“Premium outcomes today are increasingly measured by an ability to deliver both the refractive target and a high quality of vision for each patient. Since hyperosmolarity is known to have a significant negative impact on quality of vision and patient satisfaction after cataract surgery<sup>1</sup>, having an easy-to-use diagnostic tool can help surgeons meet their patients’ increasingly high expectations,” said Adam Szaronos, CEO and president of Trukera Medical. “By joining a global leader like Bausch + Lomb, we are excited to get this valuable tool in the hands of more surgeons to benefit more patients.”

DED is prevalent in cataract surgery candidates, though many are asymptomatic. In one study<sup>2</sup> looking at patients with no history of OSD, over 50 percent had an abnormal tear osmolarity or matrix metalloproteinase-9 level when presenting for surgery. In another study looking at cataract outcomes, hyperosmolar patients reported seven times the frequency of post-op dissatisfaction at the one-month mark compared to the normal osmolarity control group.<sup>1</sup>

Despite these statistics, a gap exists between the need for, and implementation of, preoperative testing. In a survey conducted by the America Society of Cataract and Refractive Surgery (ASCRS), less than 10 percent of surgeons reported using point-of-care diagnostic testing in preoperative assessments, despite over 90 percent of respondents agreeing that even mild-to-moderate DED affected patient satisfaction after cataract and refractive surgery. The ASCRS Cornea Clinical Committee has developed a protocol for cataract and refractive surgery that recognizes tear osmolarity as an essential test for identifying visually significant OSD.<sup>3</sup>

“As ophthalmic surgeons, we are committed to using every available measure to ensure the best post-surgical outcomes for our patients,” said Lisa M. Nijm, MD, JD, Warrenville Eye Care and LASIK Center in Warrenville, IL, and chief medical advisor, Trukera Medical. “ScoutPro is an invaluable tool that aids us in optimizing preoperative measurements, helping me provide exceptional refractive outcomes and high patient satisfaction.”

###

### **About ScoutPro®**

The ScoutPro Osmolarity System is an automated device intended to quantitatively measure the osmolarity of human tears to aid in the diagnosis of dry eye disease, in patients suspected of having dry eye disease in conjunction with other methods of clinical evaluation.

### **About Trukera Medical**

Founded in 2009, Trukera (formerly TearLab) was built upon the recognition of the importance of corneal health to eye care practices. The company introduced tear osmolarity testing to eye care with the TearLab Osmolarity System, which has been used to perform over 24 million tests worldwide. In 2022, the company changed its name to Trukera Medical as it expanded into corneal health. What began with a focus on osmolarity testing is now a comprehensive corneal health company working to address additional unmet needs in eye care.

### **About Bausch + Lomb**

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing, and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit [www.bausch.com](http://www.bausch.com) and connect with us on [X](#), [LinkedIn](#), [Facebook](#) and [Instagram](#).

### **Forward-looking Statements**

This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “will,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

### **References**

1. Kursite A, Laganovska G. Effect of tear osmolarity on postoperative refractive error after cataract surgery. *J.ophthalmol. (Ukraine)* 2023 Apr. 25;(2):11-5.
2. Gupta, PK, et al. Prevalence of ocular surface dysfunction in patients presenting for cataract surgery. *J Cataract Refract Surg* 2018; 44:1090-1096.
3. Starr CE, et al. ASCRS Cornea Clinical Committee. An algorithm for the preoperative diagnosis and treatment of ocular surface disorders. *J Cataract Refract Surg.* 2019 May;45(5):669-684.

© 2024 Bausch + Lomb.  
BLNP.0140.USA.24

**Media Contact:**

Caryn Marshall

[caryn.marshall@bausch.com](mailto:caryn.marshall@bausch.com)

(908) 493-1381

**Investor Contact:**

George Gadkowski

[george.gadkowski@bausch.com](mailto:george.gadkowski@bausch.com)

(877) 354-3705 (toll free)

(908) 927-0735